GLP-1 weight-loss drugs linked to inadequate intake of key nutrients in some people

A small exploratory study suggests that patients using GLP-1 weight-loss drugs like Wegovy and Mounjaro may experience inadequate intake of essential nutrients. Researchers found low awareness of these nutritional risks among patients and limited guidance from clinicians.
Why it matters
As the popularity of weight-loss drugs surges, understanding their long-term impact on dietary health is crucial for patient safety and clinical practice.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: https://kaboompics.com/ from Pexels Drugs taken to suppress appetite, such as Wegovy and Mounjaro, are associated with inadequate intakes of key nutrients and energy in some people, finds a small exploratory study published in the journal BMJ Nutrition Prevention & Health .
But there's low awareness of this potential side effect among those taking these drugs amid limited nutritional guidance from clinicians, the findings suggest.
Appetite suppressants are effective treatments for obesity and type 2 diabetes, but little is known about their impact on dietary intake, particularly because appetite suppression may reduce overall food consumption and therefore reduce nutritional intake, say the researchers.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in